GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CEO Katherine Stueland sold 3,692 shares of the company’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $84.22, for a total transaction of $310,940.24. Following the completion of the sale, the chief executive officer directly owned 107,227 shares of the company’s stock, valued at $9,030,657.94. This trade represents a 3.33% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Katherine Stueland also recently made the following trade(s):
- On Tuesday, June 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $60.77, for a total transaction of $638,145.77.
GeneDx Stock Performance
NASDAQ WGS opened at $85.26 on Friday. The company has a 50-day simple moving average of $74.67 and a two-hundred day simple moving average of $66.78. GeneDx Holdings Corp. has a 12-month low of $32.21 and a 12-month high of $170.87. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -23.42 and a beta of 1.99. The company has a quick ratio of 3.06, a current ratio of 3.30 and a debt-to-equity ratio of 0.40.
Analyst Ratings Changes
A number of equities research analysts recently commented on WGS shares. Guggenheim reiterated a “buy” rating and set a $74.00 price target (up from $70.00) on shares of GeneDx in a report on Monday, June 29th. BTIG Research restated a “buy” rating and issued a $90.00 price objective on shares of GeneDx in a research report on Tuesday, August 4th. Wall Street Zen raised shares of GeneDx from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings upgraded shares of GeneDx from a “sell (e+)” rating to a “sell (d)” rating in a report on Tuesday, August 4th. Finally, Piper Sandler reissued an “overweight” rating and issued a $63.00 target price (up from $50.00) on shares of GeneDx in a research note on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and a consensus price target of $89.57.
Get Our Latest Stock Analysis on GeneDx
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its stake in shares of GeneDx by 30.2% during the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after purchasing an additional 6,840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after buying an additional 453 shares in the last quarter. NewEdge Advisors LLC raised its stake in GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after buying an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in GeneDx by 67.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after buying an additional 11,375 shares during the period. Finally, Cetera Investment Advisers purchased a new stake in GeneDx in the second quarter worth about $249,000. 61.72% of the stock is currently owned by institutional investors.
GeneDx Company Profile
GeneDx Holdings Corp., doing business as GeneDx, is a healthcare company focused on genetic testing and genomic diagnostics. The company provides testing designed to help healthcare professionals diagnose rare and inherited conditions, guide clinical management, and support research into genetic disease.
Its offerings include whole exome and whole genome sequencing, targeted genetic tests, chromosomal microarray analysis, and other tests used to identify disease-causing genetic variants.
Featured Articles
- Five stocks we like better than GeneDx
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
